The inhibition of the enzyme soluble epoxide hydrolase (sEH) has demonstrated clinical therapeutic effects in several peripheral inflammatory-related diseases, with two compounds that have entered clinical trials. However, the role of this enzyme in the neuroinflammation process has been largely neglected. Herein, we disclose the pharmacological validation of sEH as a novel target for the treatment of Alzheimer's Disease (AD). Of interest, we have found that sEH is upregulated in brains from AD patients. We have evaluated the cognitive impairment and the pathological hallmarks in two models of age-related cognitive decline and AD using three structurally different and potent sEH inhibitors as chemical probes. Our findings supported our expectations on the beneficial effects of central sEH inhibition, regarding of reducing cognitive impairment, tau hyperphosphorylation pathology and the number of amyloid plaques.
INTRODUCTION
Chronic inflammation is recognized as a key player in both onset and progression of Alzheimer's Disease (AD) (1) (2) (3) . Indeed, 16% of the investment in ongoing clinical trials for AD is related to inflammation (4) . Neuroinflammation is intimately linked to the oxidative stress (OS) associated with AD (5, 6) , controlling the interactions between the immune system and the nervous system (7, 8) . However, several antioxidant therapies and non-steroidal anti-inflammatory drugs have failed in clinical trials. Therefore, it is of vital importance to expand the scope towards novel targets, preferably related with several pathophysiological pathways of the disease (9) .
Epoxyeicosatrienoic acids (EETs) mediate vasodilatation, reduce inflammation, attenuate OS and block the pathological endoplasmic reticulum (ER) stress response (10, 11) . The soluble epoxide hydrolase enzyme (sEH, EC 3.3.2.10, EPHX2), widely expressed in relatively high abundance in the murine and human brains (12, 13) , converts EETs and other epoxyfatty acids (EpFA) to their corresponding dihydroxyeicosatrienoic acids (DHETs), whereby diminishing, eliminating, or altering the beneficial effects of EETs (14) (Fig. 1) . Metabolism via the cyclooxygenase (COX) and lipoxygenase (LOX) pathways gives rise to largely pro-inflammatory and pro-algesic metabolites. Both pathways have been pharmaceutically targeted. CYP enzymes either hydroxylate or epoxidize AA leading to hydroxyeicosatetranoic acids (HETEs) or epoxyeicosatrienoic acids (EETs), respectively.
The latters, which are endowed with potent anti-inflammatory properties, are rapidly subjected to hydrolysis to their corresponding diols by the soluble epoxide hydrolase (sEH) enzyme. Inhibitors of sEH block this degradation and stabilize EETs levels in vivo (14) .
Major CYPs that oxidize AA are listed in the figure, but many others make a contribution.
Considering that several lines of evidence underline a broad involvement of signaling by EETs and other EpFA in the central nervous system (CNS) function and disease (15, 16) , we hypothesized that brain penetrant sEH inhibitors would stabilize EETs in the brain, resulting in a reduction of reactive oxygen species (ROS) and diminished neuroinflammation and neurodegeneration leading to a positive outcome in AD. Of interest, we found that sEH is overexpressed in brain tissues from human AD patients in Braak stage V ( Fig. 2A and table S1 ).
We also found sEH overexpressed in the hippocampus tissues of two murine models, 5xFAD (early on-set AD, Fig. 2B ) and SAMP8 (late onset AD, Fig. 2B ), supporting a crucial role of this enzyme in the disease.
RESULTS

On-target drug inhibition of sEH
We evaluated the pathological hallmarks and the cognitive impairment associated with AD using three structurally different sEH inhibitors as chemical probes (17) : TPPU (UC1770, IC50 for human sEH = 3.7 nM) (18) , AS-2586114 (IC50 for human sEH = 0.4 nM) (19) , and UB-EV-52 (IC50 for human sEH = 9 nM) (20) (Fig. 2C ). Previous pharmacokinetic data suggest that TPPU, a very well characterized sEH inhibitor, can enter into the brain (21) (22) . It is known that AS-2586114 has a prolonged action in vivo and ability to cross the blood-brain barrier (23) (24) . UB-EV-52 is a new inhibitor somewhat related with previously reported adamantane-derived sEH inhibitors such as t-AUCB (25) and the clinically studied AR9281 (UC1153) (26) . To determine whether UB-EV-52 possesses drug-like characteristics, we performed in vitro ADMET assays. We found that UB-EV-52 has excellent solubility (>100 µM at 37 °C in 5% DMSO: 95% PBS buffer), good microsomal stability (table S2) and does not inhibit cytochromes neither hERG (table S3) .
Of relevance, some cytochromes are potential off-target of sEH ( Fig. 1 ), since they are situated up stream in the arachidonic acid cascade. UB-EV-52 showed less than 5% inhibition of the studied cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP3A4 and CYP2D6) at 10 µM (table S3 ). In order to characterize the toxicity of UB-EV-52, we evaluated cell viability in human neuroblastoma SH-SY5Y cells, using a MTT assay for cell metabolic activity and a propidium iodide stain assay for cell death. In both assays, UB-EV-52 showed no cytotoxicity at 1, 10, 50 and 100 µM.
To evaluate whether sEH is the direct binding target of the inhibitors in brain tissue, we performed an in vivo thermal shift assay (CETSA) (27) . The results showed a significant shift in the sEH melting curve of the hippocampus of CD-1 mice orally treated with TPPU, AS-2586114 and UB-EV-52, demonstrating in vivo compound-induced target stabilization, providing also evidence of central action (Fig. 2D ). Control.
sEH inhibitors reduce biomarkers of inflammation, oxidation stress and endoplasmatic reticulum stress
Indicators of brain neuroinflammation were determined after treatment of SAMP8 mice with TPPU (5 mg/kg/day), AS-2586114 (7.5 mg/kg/day), and UB-EV-52 (5 mg/kg/day) ( Fig. 3A and fig. S1). The three inhibitors reduced gene expression and protein levels of the pro-inflammatory cytokines Il-1β, Ccl3 and, importantly, Tnf-α ( Fig. 3B ). Of note, TNF-α is not only involved in AD-related brain neuroinflammation, but also contributes to amyloidogenesis via β-secretase regulation (28) . Additionally, these results suggest an involvement of the two main inflammasomesignaling pathways, NF-kβ and NLRP3 (29) .
To investigate the influence of the sEH inhibitors in the OS process, we determined the concentration of hydrogen peroxide in the brain of SAMP8 mice. The three inhibitors significantly reduce hydrogen peroxide ( Fig. 3C ). Moreover, determination of the brain oxidative machinery was addressed by evaluating gene expression of Hmox1, Aox1 and protein levels of SOD1 ( Fig.   3C ). Hmox1 (antioxidant activity) (30) was significantly increased by UB-EV-52 and TPPU, but not by AS-2586114 ( Fig. 3C ). qPCR analysis also demonstrated that treated SAMP8 mice had lower Aox1 expression ( Fig. 3C ). Aox1 controls the production of hydrogen peroxide and, under certain conditions, can catalyze the formation of superoxide (31) . Furthermore, SOD1 (antioxidant activity) protein levels were significantly increased in all treated groups of mice ( Fig. 3C ), indicating a reinforcement of the antioxidant response after treatment with sEH inhibitors (32) .
It is known that the ER stress plays a role in the pathogenesis of neurodegenerative disease, including AD (33) , and those sEH inhibitors attenuate activation of the ER stress response (10) . Therefore, we measured the levels of the ER stress sensors ATF-6 and IRE1α (Fig. 3D ). Specially, UB-EV-52 was able to reduce the levels of both proteins. Furthermore, we evaluated XBP1, a major regulator of the unfolded protein response, which is induced by ER stress (33) . XBP1 was significantly reduced by UB-EV-52 and slightly decreased by AS-2586114, but not by TPPU ( Fig.   3D ). Altogether, these results suggest that the inhibition of sEH protects against OS and the associated ER stress in the brain. 
sEH inhibitors modify the two-main physio-pathological hallmarks of AD
The brains of patients with AD contain two main physio-pathological hallmarks: tangles of hyperphosphorylated tau protein and aggregates of β-amyloid (βA). After treatment of SAMP8 and 5xFAD mice with TPPU (5 mg/kg/day), AS-2586114 (7.5 mg/kg/day), and UB-EV-52 (5 mg/kg/day), on the one hand, sEH inhibition provoked a reduction of the tau hyperphosphorylated species (Ser396 and Ser404), especially Ser404, ( Fig. 4A and 4B) in agreement with the idea that OS can promote tau hyperphosphorylation and aggregation (34, 35) . On the other hand, we examined the ability of the sEH inhibitors to modify the amyloid processing cascade. While the 5xFAD transgenic mouse model develops early aggressive hallmarks of amyloid burden and cognitive loss (36), SAMP8 is characterized by an abnormal amyloid precursor protein (APP) processing, with a misbalance to the amyloidogenic pathway. Importantly, C-terminal fragments (CTF) levels are strongly implicated in neurodegeneration and the cognitive decline process in SAMP8 (37) . We observed a substantial decrease of the ratio CTFs/APP protein levels in both mice models after treatment with sEH inhibitors ( Fig. 4C and 4D ). In addition, an increase of the sAPPα, and a decrease of sAPPβ supported that sEH inhibitors are able to shift the APP processing towards the non-amyloidogenic pathway, reducing then the probability of increasing βA aggregation. Finally, treatment of 5xFAD mice with sEH inhibitors had a strong effect in reducing the number of βA plaques stained with Thioflavin-S (by an average of 40%) ( Fig. 4E ), indicating the prevention of amyloid burden in a model characterized by βA plaque formation at early ages as two months. table S4 and table S5 .
sEH inhibitors reduce cognitive impairment
To demonstrate the efficacy on the cognitive decline of the sEH inhibitors, a novel object recognition test (NORT) was performed to obtain a measure of cognition for short-term and longterm memory. Treatment of both murine models with the three sEH inhibitors drastically increased the Discrimination Index (DI). The significant increase indicates clear preservation of both memories ( Fig. 5A and 5B ). In both models, we add a comparator arm with donepezil, which is a standard of care in the treatment of AD. As expected, donepezil treatment (5 mg/kg/day) also shifted the DI to values significantly higher than zero. Remarkably, in all the conditions the sEH inhibitors reduced cognitive decline better than donepezil. table S4 and table S5 .
DISCUSSION
Our results suggest that the pharmacological stabilization of EETs in the brain has the potential to address multiples etiologies and physio-pathological processes of AD, i.e., neuroinflamation, ER stress and OS, increasing the chances of success of future therapies based on sEH inhibition.
Although the positive role of sEH inhibition in multiple inflammation-related diseases has been studied, there are only a few investigations about its crucial role in the neuroinflammation process (15, 16, 23) . In addition, the question if neuroinflammation is the malicious driver or 'just' a consequence still represents an important conundrum in the AD field. Our findings reinforce the idea that neuroinflammation might drive the pathogenic process in AD. A partial correlation calculation has demonstrated that the anti-inflammatory effects of sEH inhibitors correspond with changes in AD hallmarks, slowing the progression of the disease and pushing up the cognitive capabilities in the studied animal models.
While a characteristic feature of acute inflammatory processes is a general increase in the levels of classic eicosanoids (prostaglandins, leukotrienes and thromboxanes) in neurodegenerative diseases there is a basal, chronic and silent inflammation that is more related with an increase of the proinflammatory cytokines and inhibition of anti-inflammatory cytokines and by acting on different mechanisms implied in neurodegeneration (e.g., increase of the OS, increase in the glutamate pathway, etc.). This allowed us to anticipate different biological and therapeutic outcomes for sEH inhibition than for the COX and LOX pathway inhibition.
The fact that two structurally different sEH inhibitors have proven to be safe in human clinical trials for other peripheral indications (AR9281 for hypertension and GSK2256294 for diabetes mellitus, chronic pulmonary obstructive disease and subarachnoid hemorrhage) (26, 38) can, undoubtedly, accelerate the development of new sEH inhibitors for the treatment of AD and avoid uncertainties about the possibility of angiogenic effects when inhibiting sEH. Of relevance, for this study we have employed three structurally different sEH inhibitors, ensuring that the biological outcomes observed are not due to off-target effects related with a particular inhibitor.
In summary, we have demonstrated that sEH levels are altered in AD mice models and, more importantly, in the brain of AD patients. We have further showed that the inhibition of sEH has a plethora of central beneficial effects, such as reducing inflammation and ER stress and OS markers, p-Tau pathology and the amyloid burden and, consequently, sEH inhibitors improve the functional efficacy endpoint for cognitive status in neurodegeneration and AD animal models.
Based in the results presented in this work, we strongly believe that inhibitors of sEH could represent a completely new stand-alone treatment for the treatment of AD. However herein we do not demonstrate, and it out of the scope of this study, if inhibition of sEH could also represent an add-on therapy together with more symptomatic-like drugs i.e. donepezil. 
MATERIALS AND METHODS
Chemicals
Animals
The Senescence-Accelerated Prone Mouse 8 (SAMP8), a non-transgenic mouse, was established through phenotypic selection of the AKR/J mice strain and is an attractive model to study aging processes and, specially, age-related deterioration in learning and memory, emotional disorders and neurochemical alterations around 5 months of age (39) (40) (41) . Some of the changes in the mice are directly related to AD such as APP processing alteration and Tau hyperphosphorylation (42) .
Moreover, these animals manifest evidence of early alterations in OS and inflammation (43) .
The 5xFAD is a double transgenic APP/PS1 that co-expresses five mutations of AD and that rapidly develops severe amyloid pathology with high levels of intraneuronal Aβ42 around 2 
20-
Week old male SAMP8 mice (n = 48) and 16-week-old male 5xFAD mice (n = 48) were used to carry out cognitive and molecular analyses. The animals were randomly allocated to experimental groups. We divided these animals into eight groups: SAMP8 Control (n = 12) and 5xFAD Control (n = 12), animals administered with vehicle (2-hydroxypropyl)-β-cyclodextrin 1.8%, and both strains treated with different sEH inhibitors: TPPU (TPPU, n = 12) at 5 mg/Kg/day, AS-2586114 (AS-2586114, n = 12) at 7.5 mg/Kg/day and UB-EV-52 (UB-EV-52, n = 12) at 5 mg/Kg/day. sEH inhibitors were administered through drinking water for 4 weeks diluted in 1.8%
(2-hydroxypropyl)-β-cyclodextrin. Water consumption was controlled each week and the sEH inhibitor concentration was adjusted accordingly to reach the precise dose.
Animals had free access to food and water, and were kept under standard temperature conditions (22 ± 2 °C) and 12 hours: 12 hours light-dark cycles (300 lux/0 lux).
Studies and procedures involving mouse brain dissection and extractions were performed in accordance with the institutional guidelines for the care and use of laboratory animals and approved by the Ethics Committee for Animal Experimentation at the University of Barcelona.
Novel Object Recognition Test
This test allows evaluating short-and long-term recognition memory involving cortical areas and the hippocampus (46) . The experimental apparatus used for this test was a 90-degree, two-arm, 25-cm-long, 20-cm-high maze of black polyvinyl chloride. Light intensity in the middle of the field was 30 lux. First, mice were individually habituated to the apparatus for 10 min per day during 3 days. On the day four, the animals were allowed to freely explore 10 min acquisition trial (First trial), during which they were placed in the maze in the presence of two identical novel objects (A and A or B and B) placed at the end of each arm. The mouse was then removed from the apparatus and returned to its home cage. A 10-min retention trial (second trial) was carried out 2 hours (short-term memory) or 24 hours (long-term memory) later. During this second trial, objects A and B were placed in the maze, and the times that the animal took to explore the novel object (TN) and the old object (TO) were recorded. 24 hours after the acquisition trial, the mice were tested again, with a new object and an object identical to the new one in the previous trial (A and C or B and C). The time that mice explored the TN and time that mice explored the TO were measured from the video recordings from each trial session. A Discrimination Index (DI) was defined as (TN-TO)/(TN+TO). Exploration of an object by a mouse was defined as pointing the nose towards the object at a distance ≤ 2 cm and/or touching it with the nose. Turning or sitting around the object was not considered exploration. In order to avoid object preference biases, objects A and B were counterbalanced so that one half of the animals in each experimental group were first exposed to object A and then to object B, whereas the other half first saw object B and then object A. The maze, the surface, and the objects were cleaned with 70% ethanol between the animals' trials so as to eliminate olfactory cues.
Biochemical experiments
Murine brain tissue preparation
SAMP8 mice were euthanized 3 days after the behavioural test completion by cervical dislocation.
Brains were immediately removed from the skull. Cortex and hippocampus were then isolated and frozen on powdered dry ice. They were maintained at -80 °C for biochemical experiments.
5xFAD mice were anesthetized with pentobarbital 3 days after behavioral test completion and transcardially perfused with saline. Afterward, brains were dissected. One hemisphere was postfixed overnight in 4% PFA with 15% sucrose at 4 °C, while the other hemisphere was dissected into cortex and hippocampus, frozen on powdered dry ice and maintained at -80 °C for further biochemical experiments.
Human cases
Tissue samples were obtained from the Institute of Neuropathology-IDIBELL Brain Bank, Hospitalet de Llobregat following the guidelines of Spanish legislation on this matter and the approval of the local ethics committee. The interval between death and autopsy was between 1 to 10 hours (fig. S1 ). The brain tissue was immediately frozen on metal plates over dry ice, placed in individual air-tight plastic bags, and maintained at -80 °C for biochemical experiments.
Neuropathologic diagnosis of AD was based on the classification of Braak and Braak (47, 48) .
Protein levels determination by Western blotting
For Western blotting (WB), aliquots of 15 µg of hippocampal protein were extracted with lysis buffer containing phosphatase and protease inhibitors (Cocktail II, Sigma) and protein concentration was determined by Bradford's method. Protein samples from 24 mice of both strains (n = 3 per group) were separated by SDS-PAGE (8-20%) and transferred onto PVDF membranes (Millipore). Afterward, membranes were blocked in 5% non-fat milk in 0.1% Tween20-TBS (TBS-T) for 1 hour at room temperature, followed by overnight incubation at 4 ºC with the primary antibodies, that are presented in Table 1 .
The next day, membranes were washed with TBS-T and incubated with secondary antibodies for 1 hour at room temperature. Immunoreactive proteins were viewed with a chemiluminescencebased detection kit, following the manufacturer's protocol (ECL Kit, Millipore) and digital images were acquired using a ChemiDoc XRS+System (BioRad). Semi-quantitative analyses were carried out using ImageLab Software (BioRad) and results were expressed in Arbitrary Units (AU), considering the control mice group as 100%. Protein loading was routinely monitored by immunodetection of GAPDH. 
Antibody
Protein levels determination by ELISA
Immunoreactive IL-1β, TNF-α, and CCL3 protein levels from 40 mice of both strains (n = 4-5 per group) were determined using mouse-specific ELISA kits according to manufacturer's instructions Equivalent amounts of proteins were used for the analyses. Cytokine levels were expressed as pg/mg of protein.
RNA extraction and gene expression determination
Total RNA isolation was carried out using TRIzol® reagent according to manufacturer's instructions. The yield, purity, and quality of RNA were determined spectrophotometrically with a NanoDrop ™ ND-1000 (Thermo Scientific) apparatus and an Agilent 2100B Bioanalyzer (Agilent Technologies). RNAs with 260/280 ratios and RIN higher than 1.9 and 7.5, respectively, were selected. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) was performed as follows: Data were analyzed utilizing the comparative Cycle threshold (Ct) method (ΔΔCt), where the housekeeping gene level was used to normalize differences in sample loading and preparation (49) .
Normalization of expression levels was performed with β-actin for SYBR ® Green-based real-time PCR and TATA-binding protein (Tbp) for TaqMan-based real-time PCR. Primers sequences and
TaqMan probes used in this study are presented in Table 2 . Each sample was analyzed in duplicate, and the results represent the n-fold difference of the transcript levels among different groups. Tbp 93 Mm00446971_m1 Table 2 . Primers and probes used in qPCR studies.
SYBR Green primers
Aβ plaque histology
Amyloid plaques from 16 5xFAD mice (n = 4 per group) were stained with Thioflavin-S. The frozen brains were embedded into OCT Cryostat Embedding Compound (Tissue-Tek, Torrance, CA, USA) and then cut into 20 µm-thick sections at -20 °C using a cryostat (Leica Microsystems, Germany) and placed on slides. For the Thioflavin-S staining procedure, the brain sections were first rehydrated at room temperature by 5 min incubation in PBS. To continue with, brain sections were incubated with 0.3% Thioflavin-S (Sigma-Aldrich) solution for 20 min at room temperature in the dark. Subsequently, these samples were submitted to washes in 3 min series, specifically with two washes using 80% ethanol, one wash using 90% ethanol and three washes with PBS.
Then, slides were mounted with Fluoromount-G TM (EMS, Hatfield, NJ, USA) and allowed to dry overnight. Image acquisition was performed with a fluorescence laser microscope (Olympus BX51; Germany). For plaque quantification, similar and comparable histological areas were selected, focusing on the adjacent positioning of the whole cortical area and the hippocampus.
Determination of oxidative stress
Hydrogen peroxide from 40 hippocampus samples of mice of both strains (n = 5 per group) was measured as an indicator of oxidative stress and it was quantified using the Hydrogen Peroxide Assay Kit (Sigma-Aldrich, St. Louis, MI) according to the manufacturer's instructions.
Thermal Shift Assay (CETSA) for in vivo brain tissue
The Thermal Shift Assay (TSA) was carried out based on a previously described protocol with modifications (27, 50, 51) . For the in vivo hippocampus tissue TSA experiment, male CD-1 mice 8-week-old (35-45 g; n = 3 per group) were treated with a single dose of each sEH inhibitor at 5 mg/Kg for TPPU, 7.5 mg/Kg for AS-2586114 and 5 mg/Kg for UB-EV-52, by intraperitoneal injection (IP) in 20% of (2-hydroxypropyl)-β-cyclodextrin, and, after one hour and a half, mice were euthanized by cervical dislocation. Immediately, brains were removed from the skull, frozen on the powdered dry ice and were maintained at -80 °C.
The brains from the different above-mentioned groups were homogenized in 200 μL PBS with EDTA 5 mM and complete protease inhibitor cocktail II (Sigma Thermal Cycler). Immediately, homogenates were incubated at room temperature (25 °C water bath) for 5 min and lysed with freeze-thawed three times using liquid nitrogen. Then, the supernatant fraction for each 7-point temperature homogenate from each treatment group was separated from the cellular debris and protein aggregates by centrifugation at 20,000 g for 20 min at 4 °C, and the duplicate of 7-point temperature gradient without centrifugation were the whole fraction. All these 14 samples for each treatment were transferred to new microtubes and analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by western blotting analysis by using rabbit monoclonal anti-EPHX2 antibody as described above. The appropriate temperatures were determined in preliminary TSA experiments (Data not shown).
Data analysis
The statistical analysis was conducted using GraphPad Prism ver.6 statistical software. Data were expressed as the mean ± Standard Error of the Mean (SEM) from at least 3 samples per group.
Means were compared to One-Way ANOVA analysis of variance, followed by Dunnett's post-hoc analysis. Comparison between groups were also performed by two-tail Student's t-test for independent samples. Statistical significance was considered when p-values were <0.05. The statistical outliers were carried out with Grubss' test and subsequently removed from the analysis.
Behavioral analyses were performed blindly.
In addition, partial correlation controlling for each strain was calculated using SPSS 21 
Microsomal stability of human, rat and mice microsomes
The human, rat and mice microsomes employed were purchased from Tebu-Xenotech. The compound was incubated at 37 °C with the microsomes in a 50 mM phosphate buffer (pH = 7.4) containing 3 mM MgCl2, 1 mM NADP, 10 mM glucose-6-phosphate and 1 U/mL glucose-6phosphate-dehydrogenase. Samples (75 µL) were taken from each well at 0, 10, 20, 40 and 60 min and transferred to a plate containing 4 °C 75 µL acetonitrile and 30 µL of 0.5% formic acid in water were added for improving the chromatographic conditions. The plate was centrifuged (46000 g, 30 min) and supernatants were taken and analyzed in a UPLC-MS/MS (Xevo-TQD, Waters) by employing a BEH C18 column and an isocratic gradient of 0.1% formic acid in water: 0.1% formic acid acetonitrile (60:40). The metabolic stability of the compounds was calculated from the logarithm of the remaining compounds at each of the time points studied.
Cytochrome inhibition
The human cytochrome isoforms were purchased from Corning unless CYP2C19 that was purchased from Cypex. Compounds were incubated for 5 min at 37 °C in 50 mM phosphate buffer The cells (80 μL/well) were added to the plate and the hERG activity was registered beginning with a 5 seconds depolarization phase (from -80 mV to +20 mV) followed by a 5-second tail at -50 mV and a repolarization at -80 mV. This cycle was repeated every 15 seconds. Current inhibition was calculated from Ionflux Data Analyzer software (V4.6) from the basal activity of the channel.
Solubility
A 10 mM stock solution of the compound was serially diluted in 100% DMSO and 2.5 µL of this solution was added to a 384-well UV-transparent plate (Greiner) containing 47.5 µL of PBS. The plate was incubated at 37 °C for 4 h and the light scattering was measured in a Nephelostar Plus reader (BMG LABTECH). The data was fitted to a segmented linear regression for measuring the compound solubility.
Cytotoxicity
Cytotoxicity was evaluated in the human neuroblastoma cell line SH-SY5Y (ATCC Number: CRL-2266). Cells were cultured in a mixture of 50% Minimum Essential Medium, 50% Ham's-F12 medium, 10% fetal bovine serum, 1% L-glutamine, 1% MEM non-essential amino acids and 0.1% of gentamicin. The cells were seeded in 96-well plate at a concentration of 3·10 5 cells/mL. After 24 h, the testing compounds were added by triplicate at different concentration up to 100 µM and incubated for further 24 h. Cytotoxicity was sequentially analysed by performing the propidium iodide (PI) fluorescence stain assay and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay, as described elsewhere (52) . Briefly, cell death was measured by PI staining. The PI reagent was added to each well and incubated for 1 h, and the fluorescence was measured by Gemini XPS Microplate reader (Millipore) at 530 nm excitation and 645 nm emission, and the relative number of cell death was calculated. Cell metabolic activity was determined by the MTT assay. The MTT reagent was added to each well and incubated for 2 h in the cell incubator, then a lysis buffer was added and further incubated at 37 °C overnight. The colorimetric reaction was measured by Multiskan Spectrum Spectrophotometer (Thermo) at 570 nm and a reference 630 nm wavelength. Experiments were performed three times at different cell passages.
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